Trial Profile
A Multicenter, Randomized, Placebo-controlled, Double-blind Study on the Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease (ESRD) in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- Acronyms ADPKD
- Sponsors Novartis
- 24 May 2014 New trial record